Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM512 in Perennial Allergic Rhinitis
NCT07890350Phase 2Not yet recruiting
- Sponsor
- Keymed Biosciences
- Start
- Oct 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of CM512 in perennial allergic rhinitis (PAR), sponsored by Keymed Biosciences. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
CM512
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT07890350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890350.